Ablation efficacy for non-distant metastases differentiated thyroid carcinoma with low-dose 131I / 中华核医学与分子影像杂志

ABSTRACT

Objective To investigate the efficacy of thyroid ablation with low dose (1 110 MBq) 131 I for non-distant metastases differentiated thyroid carcinoma (DTC) and its probable influence factors.Methods A total of 183 DTC patients (48 males,135 females,average age(39.75±10.14) years) treated by thyroid ablation with 1 110 MBq 131I from January 2015 to December 2016 were respectively observed.All patients underwent diagnostic whole body scan (Dx-WBS) and the stimulated thyroglobulin (sTg) was measured 6-9 months after thyroid ablation.According to the results,patients were divided into successful ablation group (G1) and unsuccessful group (G2).Clinical and pathological characteristics of 2 groups were compared by two-sample t test,Mann-Whitney u test andx2 test.Logistic regression was used to identify the influence factors for efficacy of 131I ablation,and the cutoff value was determined by receiver operating characteristic (ROC) curve analysis.Results There were 156 patients in G1 and 27 patients in G2.The successful ablation rate was 85.25％(156/183).Comparing with patients in G2,patients in G1 showed higher thyroid stimulating hormone (TSH) before ablation and lower sTg.The TSH level was 137.94(124.21,150.00) and 74.91(55.57,98.18) mU/L respectively (u=6.458,P＜0.05),and sTg was 1.80(0.69,5.20) and 22.30(4.49,32.20) μg/L respectively (u=-6.174,P＜0.05).Logistic regression showed that TSH,sTg and T stage before ablation were independent predictors for efficacy of 131I ablation (odds ratios0.357-0.944).The optimal cutoff values of TSH and sTg identified by ROC curve analysis were 122.98 mU/L and 13.78 μg/L.Conclusions Low-dose 131I is effective enough for ablation treatment in non-distant metastases DTC patients with low T stage and low sTg(＜ 13.78 μg/L).High TSH (＞ 122.98 mU/L) before ablation may facilitate the efficacy of 131I ablation.